Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$39.46 -16.8%	$40.36	$26.20 ▼ $76.39	$1.82B	1.47	580,683 shs	4.25 million shs
CGON CG Oncology	$26.24 -2.5%	$25.97	$14.80 ▼ $40.47	$2.00B	0.86	846,623 shs	197,846 shs
HHH Howard Hughes	$68.59 -0.5%	$68.79	$59.83 ▼ $87.77	$3.46B	1.21	374,363 shs	259,172 shs
TSHA Taysha Gene Therapies	$2.37 -3.5%	$2.50	$1.05 ▼ $3.31	$507.67M	0.97	2.92 million shs	403,691 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+9.61%	+16.03%	+47.21%	+25.07%
CGON CG Oncology	0.00%	+3.64%	-0.06%	+58.95%	-15.64%
HHH Howard Hughes	0.00%	+2.35%	+1.00%	+7.28%	+7.44%
TSHA Taysha Gene Therapies	0.00%	+0.84%	-15.49%	+93.55%	+15.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	2.8804 of 5 stars	3.5	2.0	2.4	4.2	0.0
CGON CG Oncology	2.3459 of 5 stars	4.5	3.0	0.0	0.8	0.0
HHH Howard Hughes	2.8001 of 5 stars	2.3	3.0	3.0	3.3	1.3
TSHA Taysha Gene Therapies	3.2246 of 5 stars	4.5	1.0	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$95.80	142.33% Upside
CGON CG Oncology	3.00	Buy	$58.67	122.26% Upside
HHH Howard Hughes	2.67	Moderate Buy	$80.33	16.53% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.20	246.72% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, APGE, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/23/2025	HHH Howard Hughes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$82.00 ➝ $76.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/23/2025	HHH Howard Hughes	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $85.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
CGON CG Oncology	$1.14M	1,764.76	N/A	N/A	$9.63 per share	2.74
HHH Howard Hughes	$1.75B	1.98	$9.70 per share	7.11	$56.65 per share	1.22
TSHA Taysha Gene Therapies	$8.33M	60.94	N/A	N/A	$0.35 per share	6.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
HHH Howard Hughes	$200.55M	$5.21	13.24	74.93	N/A	14.27%	10.21%	3.08%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest TSHA, HHH, APGE, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
5/7/2025	Q1 2025	HHH Howard Hughes	$0.13	$0.21	+$0.08	$0.21	$187.43 million	$199.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
CGON CG Oncology	N/A	30.97	30.97
HHH Howard Hughes	1.84	1.41	1.41
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CGON CG Oncology	26.56%
HHH Howard Hughes	93.83%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CGON CG Oncology	N/A
HHH Howard Hughes	33.00%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
CGON CG Oncology	61	76.22 million	N/A	Optionable
HHH Howard Hughes	608	50.39 million	33.76 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

TSHA, HHH, APGE, and CGON Headlines

Recent News About These Companies

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock

July 1, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLC

July 1, 2025 | marketbeat.com

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

June 29, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, APGE, and CGON Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$39.66 -7.80 (-16.43%)

As of 01:39 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

CG Oncology NASDAQ:CGON

$26.19 -0.71 (-2.64%)

As of 01:39 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Howard Hughes NYSE:HHH

$68.57 -0.34 (-0.49%)

As of 01:39 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Taysha Gene Therapies NASDAQ:TSHA

$2.37 -0.09 (-3.47%)

As of 01:38 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time